Air Products to Highlight Advanced Liquid Nitrogen Technologies at INTERPHEX 2013

Company’s LIN Solutions Can Help Pharmaceutical/Biopharmaceutical Manufacturers Improve Process Efficiency and Lower Operating Costs

LEHIGH VALLEY, Pa. (April 15, 2013) – Air Products (NYSE:APD), a leading industrial gas supplier and cryogenic solutions provider, will highlight its wide range of advanced liquid nitrogen technologies (LIN)  at INTERPHEX 2013 in New York City from April 23-25. The company’s LIN solutions can address many process challenges in the pharmaceutical and biopharmaceutical industries by providing an economical and simple way of cooling for a variety of manufacturing processes.

Among the LIN solutions that Air Products will feature at the show are:

  • PolarFit® reaction cooling for fast, precise, flexible, and low-cost heat removal;
  • PolarFit® process cooling, which consists of customized solutions for processes where the cooling power of LIN can help increase productivity and product quality;
  • Cryogenic cooling technology for lyophilization, which provides improved performance and reliability with a lower capital investment compared to mechanical systems;
  • Cryo-Condap® solvent recovery system for the economical recovery and abatement of volatile organic compounds; and
  • PolarFit® grinding systems, which enable manufacturers to achieve fine particle sizes with more uniform distribution and high yields.

More detailed information about each of these technologies can be found on Air Products’ recently launched microsite at This dedicated website is designed to show pharmaceutical and biopharmaceutical manufacturers how the unique properties of liquid nitrogen can provide a variety of benefits—from increased productivity to reduced environmental impact—in their manufacturing processes.

INTERPHEX attendees can stop by booth #2478 to discuss Air Products’ complete portfolio of LIN solutions, as well as the company’s proprietary in-house computational modeling systems that can help predict the cooling profile of a customer’s reaction. This, combined with Air Products’ more than 40 years of cryogenic applications experience, enables the company to help pharmaceutical and biopharmaceutical companies identify the most efficient process cooling solution to fit their specific application.

Air Products will also highlight its full range of industrial gases, available in a variety of delivery options to match each customer’s requirements. For small volume users, the company’s CryoEase® microbulk solution offers an alternative to cylinder supply that eliminates the hassle of cylinder handling. For larger volume customers, Air Products provides traditional bulk liquid and gas supply, as well as PRISM® on-site gas generation systems. The company also offers a fast and flexible option for short-term or emergency gas supply through its Air Products Express Services. To help industrial gas users convert weight and volume measures for common industrial gases, Air Products recently developed a mobile app. The new Air Products Gas Converter app can be downloaded at

For more information about Air Products complete offerings for the pharmaceutical and biopharmaceutical industries, call 800-654-4567 (outside of the U.S. 610-706-4730) or visit

About Air Products

Air Products (NYSE:APD) provides atmospheric, process and specialty gases; performance materials; equipment; and technology. For over 70 years, the company has enabled customers to become more productive, energy efficient and sustainable. More than 20,000 employees in over 50 countries supply innovative solutions to the energy, environment and emerging markets. These include semiconductor materials, refinery hydrogen, coal gasification, natural gas liquefaction, and advanced coatings and adhesives. In fiscal 2012, Air Products had sales approaching $10 billion. For more information, visit

NOTE: This release may contain forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s reasonable expectations and assumptions as of the date of this release regarding important risk factors. Actual performance and financial results may differ materially from projections and estimates expressed in the forward-looking statements because of many factors not anticipated by management, including risk factors described in the Company’s Form 10K for its fiscal year ended September 30, 2012.